Sarah Pett

University of Liverpool — United Kingdom

Medicine · Health Sciences

14h-index8.7kcitations28works3.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

COVID-19 Clinical Research Studies(11), Long-Term Effects of COVID-19(10), SARS-CoV-2 and COVID-19 Research(5), HIV Research and Treatment(4), Influenza Virus Research Studies(4)

Publications22 total

SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial)
Scientific Reports·2025Open Access
Predictors of hospitalization, death and incomplete/non-recovery from SARS-CoV-2 in an ambulatory global population
International Journal of Infectious Diseases·2024· 1 citedOpen Access
Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19
Clinical Infectious Diseases·2024· 12 citedOpen Access
Association and Additive Risk of Respiratory and Viral Response Baseline Variables With Mortality in Therapeutics for Inpatients With COVID-19 (TICO) Platform Randomized Clinical Trial (RCT) Participants
2023· 1 cited
The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19
Annals of Internal Medicine·2022· 60 citedOpen Access
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19
Annals of Internal Medicine·2022· 30 citedOpen Access
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial
The Lancet Respiratory Medicine·2022· 124 citedOpen Access
Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery
American Journal of Respiratory and Critical Care Medicine·2022· 13 citedOpen Access
Impact of Dexamethasone and Remdesivir on Neurological Complications during COVID-19
SSRN Electronic Journal·2022· 4 citedOpen Access
Tixagevimab/Cilgavimab for Treatment of Hospitalised COVID-19 Patients: A Randomised, Double-Blind, Phase 3 Trial
SSRN Electronic Journal·2022· 3 citedOpen Access
Remdesivir for the Treatment of Covid-19 — Final Report
New England Journal of Medicine·2020· 7.6k citedOpen Access
Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial
The Lancet Respiratory Medicine·2019· 132 citedOpen Access
Influenza Immunoglobulin for Adults Hospitalized with Influenza
SSRN Electronic Journal·2019· 1 citedOpen Access
Anti-Influenza Hyperimmune Immunoglobulin Enhances Fc-Functional Antibody Immunity During Human Influenza Infection
The Journal of Infectious Diseases·2018· 11 citedOpen Access
Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study
Open Forum Infectious Diseases·2017· 16 citedOpen Access
Factors Associated With Plasma IL-6 Levels During HIV Infection
The Journal of Infectious Diseases·2015· 177 citedOpen Access
Determinants of IL‐6 levels during HIV infection
Journal of the International AIDS Society·2014· 11 citedOpen Access
The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection: Results of Two International Observational Cohort Studies
PLoS ONE·2013· 66 citedOpen Access
Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study
Clinical Trials·2012· 118 citedOpen Access
Atazanavir
2010
page 1 of 2Next →

Frequent Co-authors

Jens Lundgren(14), James D. Neaton(11), Andrew Phillips(11), Abdel G. Babiker(10), Deborah Wentworth(10), Mamta K. Jain(10), Virginia L. Kan(10), H. Clifford Lane(9), Nicole Engen(9), Ven Natarajan(9), Robin Dewar(8), Adit A. Ginde(8), Kathryn Shaw‐Saliba(8), Cavan Reilly(8), Elizabeth S. Higgs(8), Roger Paredes(7), Giota Touloumi(7), Richard T. Davey(7), Kami Kim(7), Victoria J. Davey(7)